Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, has announced the merger of Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous therapies, and Advanced Biologics (Biologica Technologies). Isto Biologics has maintained a commercial partnership with Advanced Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARCTM. SPARCTM is a novel inductive bone matrix that stemmed from Advanced Biologics’ proprietary tissue processing method used in their flagship product OsseoGEN. SPARCTM is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
Read the full article: Thompson Street Capital Partner’s Isto Biologics Merges with Advanced Biologics/Biologica Technologies //
Source: https://www.businesswire.com/news/home/20231025463003/en/Thompson-Street-Capital-Partner%E2%80%99s-Isto-Biologics-Merges-with-Advanced-BiologicsBiologica-Technologies